Plasma adipocytokines and antioxidants-status in Korean overweight and obese females with dyslipidemia

Ae Wha Ha¹, Su Youn Jeong¹, Nam E Kang² and Woo Kyoung Kim¹

¹Department of Food Science and Nutrition, Dankook University, 152 Jukjeon-Ro, Suji-Gu, Yongin-Si, Gyeonggi 448-701, Korea
²Department of Food and Nutrition, Eulji University, 553 Sanseong-Daero,Seongnam-Si, Gyeonggi 461-632, Korea

BACKGROUND/OBJECTIVES: It is hypothesized that obese people with dyslipidemia is more likely to have increased oxidative stress and decreased antioxidant status, in comparison with the controls who were obese without dyslipidemia. Thus, the aims of the present study were to determine the dietary intakes, plasma adipokines, and antioxidative systems between obese with dyslipidemia and obese without dyslipidemia were investigated.

SUBJECTS/METHODS: Female subjects who were between 20 and 55 years old, and whose BMI was 23 or greater were recruited. Subjects who met the criteria of BMI ≥ 23, total cholesterol ≥ 200 mg/dL, LDL cholesterol ≥ 130 mg/dL, and TG ≥ 110 mg/dL were categorized Obese with dyslipidemia. Anthropometric measurements and blood biochemical tests were conducted. The diet survey was conducted by a trained dietitian using two days of 24 hour dietary recall. The lipid peroxidation, the plasma total antioxidant capacity (TAC), the activities of antioxidative enzymes, and various antioxidative vitamins levels were determined.

RESULTS: Plasma adiponectin and leptin levels were also determined. There were no significant differences for age, Body Mass index (BMI), and body fat (%), waist-size between two groups. Obese with dyslipidemia had significantly high levels of total cholesterol, triglyceride, LDL-cholesterol, the ratio of total cholesterol/HDL-C, and the ratio of HDL-C /LDL-C, respectively. Blood alkaline phosphatase level was statistically different between the two groups (P < 0.05). No statistical significance in dietary intake between two groups was shown. In case of obese with dyslipidemia group, the levels of GSH-Px (P < 0.05) and catalase (P < 0.05) as well as adjusted blood retinol (P < 0.05) and tocopherol level (P < 0.05) were significantly low. However, the plasma concentration of leptin was significantly high (P < 0.05).

CONCLUSIONS: Obesity with dyslipidemia was shown to have high arthrogenic index, depleted antioxidant status, and higher blood leptin levels which suggest higher risks of oxidative stress and cardiovascular diseases.

INTRODUCTION

According to The Korea National Health and Nutrition Examination Survey (KNHANES) , the obesity rate among adult Korean was estimated at 36.8% for men and 24.8% for women [1]. Especially women, from ages 40 and above, have a rapid increase in obesity rate, 46% as well as simultaneously high rates of hypertension and dyslipidemia, which suggests that obesity is maybe associated with these aforementioned health problems [1].

Although obesity is related with the developments of chronic diseases such as cardiovascular diseases (CVD) and diabetes, not all obese people have obesity-related complications or diseases. Several studies reported that obese people with normal blood lipid profiles, glucose tolerance, or blood pressure, possess health risk that is as low as that of the normal weight people [2-4].

Dyslipidemia is defined as a condition of high blood cholesterol and triglycerides levels that can increase the risk of heart disease, stroke, and other health problems [8]. Obesity with dyslipidemia has been shown to increase the risk of developing CVD [5-7]. However, even after accounting for blood lipid profiles and blood pressure that results from dyslipidemia in obese subjects, studies reported significant association between body fat and CVDs.

In the past, adipose tissue was simply seen as a storage organ, but nowadays it has been revealed that adipose tissue not only serves as energy reserves but also as endocrine organ secreting important adipokines and cytokines [9]. Among adipokines, leptin and adiponectin are major plasma proteins secreted by adipocytes, and the plasma concentrations of leptin are markedly increased while adiponectin is decreased in obese population [9]. Several studies reported that adipokines, in
addition to its angiogenic properties, increases the generation and accumulation of free radicals, playing an important role for developing atherosclerosis [10-12].

Oxidative stress is characterized by depleting antioxidant production in body, which plays a role in preventing chronic diseases in obese people [13]. Antioxidant system in body consists of antioxidant enzymes and antioxidant vitamins. Antioxidant enzymes include catalase, superoxide dismutase, and glutathione peroxidase which may directly/indirectly contributes to defense against the reactive oxygen species (ROS). Antioxidant vitamins, such as vitamin A, vitamin E, and vitamin C, are the non-enzymatic antioxidants that serve as scavengers of ROS [14].

Though oxidative /antioxidative status in obese people is identifiable no comparison about obesity with or without dyslipidemia and oxidative stress has been made. The aims of the present study were, 1) to determine whether overall health and dietary problems occur, and to what degree, at obesity with dyslipidemia and, 2) to assess the oxidative stress and antioxidants balance in the two group subjects.

SUBJECTS AND METHODS

Study design and subjects

Recruitment of subjects for this study, through the regional newspapers and hospital advertisements, was carried out at the university hospital in Korea. Subjects were selected from females who were in the age group of 20-55 years, and whose BMI was 23 or greater. None of the subjects were taking antioxidant vitamin supplements or lipid-lowering drugs. Subjects who had any chronic diseases, or who were pregnant, were excluded. The selected overweight and obese females (BMI ≥ 23) participated in the next phases of the study, such as anthropometry, biochemical test, and diet survey. This study (EMCRIB-11-116) was approved by the institutional review boards of the hospital (Seoul, Korea), in accordance with the Declaration of Helsinki. Written consent was obtained from all individuals after the purpose and nature of the study had been explained.

Anthropometric measurements

Height was measured by using a portable stadiometer to the nearest 0.1 cm by a nurse. While the subjects were standing, Waist and hip circumference were measured. Waist circumference (WC) was measured on the midway between rib cage and superior border of the iliac crest after complete expiration by using a measuring tape. Hip circumference (HC) was measured at the point yielding the maximum circumference over the hips using a measuring tape to the nearest 1 cm. Waist-hip ratio was calculated, dividing WC/HC to determine abdominal obesity. Body weight and body fat (%) were measured through the use of bioelectrical impedance analysis (In-body 3.0, Biospace, Seoul, Korea). BMI was also calculated by using weight and height data [15].

Biochemical tests

Participants were invited to attend the hospital after an overnight fast. Serum and plasma was obtained from blood samples after centrifugation (1,000 g for 10 min at 4°C). Cholesterol, triglyceride, LDL-cholesterol, and HDL-cholesterol were also determined by the instrument of automatic blood analysis (ADMA2120, SIEMENS, Washington D.C. USA). Cholesterol/ HDL-cholesterol, HDL-cholesterol/LDL-cholesterol was calculated by the known formulas [16]. General blood biochemical markers were also assayed. Hemoglobin, Albumin, Creatinine, BUN (blood urea nitrogen), GOT (glutamic oxalate transaminase), GPT (glutamic pyruvate transaminase), r-GTP (gamma-glutamyl transpeptidase), and glucose were determined by the automatic blood analyzer (ADVIA2120, SIEMENS, Washington D.C. USA). Plasma samples for oxidative stress and antioxidants measurements were kept at -20°C before analysis.

Subjects, who met the criteria of BMI ≥ 23, total cholesterol ≥ 200 mg/dL, LDL cholesterol ≥ 130 mg/dL, and TG ≥ 110 mg/dL, were categorized as obese with dyslipidemia group, and in otherwise, categorized as the control group.

Dietary intake survey from 24 hour Dietary recall

Each subjects was required to report on all the foods and drinks consumed during the previous 24 hours for 2 days (1 weekday, 1 weekend), and recorded by a trained dietitian. In order to improve the amount of dietary intake, food models and photographic manual of food portion size were used. The dietary intake data was analyzed using the software (Can Pro 4.0) developed by Korean Nutrition Association. After calculating energy and nutrients intakes, average intake was compared to the dietary reference intakes for Korean (KDRIs) and expressed as a percent KDRIs.

Blood lipid peroxidation Assay

Lipid peroxide level in plasma was determined using thiobarbituic acid (TBA) as described previously [17]. Briefly, to 100 μL of plasma, 100 μL of 8.1% (w/v) sodium dodecylsulphate, 750 μL of 20% (v/v) acetic acid (pH 3.5), 750 μL of 0.8% TBA, and water were added to make a total volume of 2 mL. The mixture was boiled for 30 min in water bath and then cooled at room temperature. Five hundred μL of cold water and 2.5 mL of butanol and pyridine [15:1 (v/v)] were added, vortexed, and then centrifuged. After centrifugation, the supernatants were measured for absorbance at 532 nm using a spectrophotometer. Standard curve using various concentrations of 1,1,3,3 - tetra ethoxy propane (TEP) were used for calculation.

Blood total antioxidant capacity Assay

The total antioxidant capacity (TAC) was measured using an antioxidant assay kit (Sigma, St Louis, Mo, USA) [18]. Trolox was used as an antioxidant standard to calculate Trolox equivalent antioxidant capacity; absorbance readings were taken at 520 nm.

Blood antioxidant enzymes Assay

Unless otherwise mentioned, all the chemicals were of analytical grade and purchased through Sigma (St. Louis, MO, USA). Catalase activity was determined using spectrophotometric method by measuring the amount of decrease in absorption at 240 nm in a reaction mixture containing phosphate buffer (0.1 mM, pH 7.0) and H2O2 (8.8 mM) according to the study of Aebe H [19]. Superoxide dismutase (SOD) was measured with a SOD determination kit.
Human enzyme immunoassay kits (RayBiotech, Inc., Georgia, USA) [20]. GSH-Px activity with H2O2 as a substrate was measured according to Paglia and Valentine [21]. The enzyme reaction in a tube containing NADPH, reduced glutathione (GSH), sodium azide, and glutathione reductase was initiated by the addition of H2O2 and change in absorbance was monitored at 340 nm.

Blood antioxidative vitamins analysis

Reagents and Chemicals

Standards of retinol, α-tocopherol, β-carotene, lycopene, lutein, and tocopherol acetate were purchased from Sigma (St. Louis, MO, USA). HPLC gradient grade methanol, ethanol, acetonitrile, methylene chloride, and n-hexane were obtained from Merck (Merck KGaA, Darmstadt, Germany).

Standards Preparation

Standard stock solutions of retinol (20 mg/mL), α-tocopherol (1 g/L), and α-tocopheryl acetate (1 g/L) were prepared in ethanol. Tocopherol acetate was used as an internal standard. Stock solutions of β-carotene (20 mg/mL), lycopene (20 mg/L), lutein (20 mg/L) were prepared in n-hexane. All stock solutions were stored at -20°C. Work solutions of individual vitamins and internal standards were prepared daily and the concentrations were verified spectrophotometrically using molar absorptions [22,23].

HPLC Instrumentation

The concentration of retinol, α-tocopherol, β-carotene, lycopene, and lutein were determined by using HPLC [22,23]. Chromatographic analysis was conducted using Waters HPLC (Milford, Massachusetts, USA) with a Waters 1,525 binary HPLC pump consisting of a Waters 2,487 dual absorbance detector. Reverse-phase HPLC equipped with SunFire C18 Column, 4.6 × 150 mm, 5 μM (Sigma, St. Louis, USA) was used for the analysis. The UV detector was set at 450 nm for carotenoids and 290 nm for retinol and α-tocopherol. The mobile phase for carotenoids consisted of acetonitrile: methylene chloride: methanol (7:2:1 by volume). The mobile phase for retinol and α-tocopherol were consisted of 100% methanol. Injection volume through HPLC was 20 μL and the flow rate was set at 1.5 mL/min. Data acquisition was completed in 30 minutes.

Sample analysis procedure

Briefly, 100 μL of the plasma sample, 10 μL of internal standard, 150 μL of ethanol were mixed and vortexed for 2 min. Hexane, 500 μL, was added, vortexed for 5 min, and then centrifuged (22,000 × g, 3 min, 4°C). This procedure was repeated twice and then the upper hexane layer was collected into 5 - mL amber glass tubes. Combined hexane extracts were dried under nitrogen. The dried residue was re-dissolved in 50 μL of mobile phase and vortexed for 60s. The sample was then filtered through a nylon filter (pore size 0.20 μM, 4 mm diameter, Supelco, Bellefonte, PA, USA) before injection.

Blood adiponectin and leptin

Adiponectin and leptin were determined separately by RayBio human enzyme immunoassay Kits (RayBiotech, Inc, Georgia, USA) [22].

Statistical analysis

The statistical analysis was conducted with SPSS Ver.19.0 (SPSS Inc., Chicago, IL, USA). The data are presented as mean ± S.D. The differences between groups were evaluated using Student’s t-test.

RESULTS

The anthropometric characteristics of the subjects

In Table 1, the mean value of BMI in all subjects was 26.7 ± 2.8 and mean of body fat (%) was 36.0 ± 4.3 (%). There were no significant differences for age, BMI, and body fat (%) between two groups, although BMI and body fat (%) were a little higher in the obese with dyslipidemia than in the control group. The mean value of WHR was 0.90 ± 0.05, which is higher than normal level, WHR < 0.85. No differences were observed for waist size and WHR between two groups.

Blood lipid concentrations of the subjects

There were significantly higher levels of total cholesterol (P < 0.001), triglyceride (P < 0.05), and LDL-cholesterol (P < 0.001) in obese with dyslipidemia compared to those of the control group (Table 2). In obese with dyslipidemia, significantly high ratio of total cholesterol/ HDL-cholesterol (P < 0.001) and LDL-cholesterol/HDL-Cholesterol (P < 0.001) were shown.

| Table 1. The anthropometric characteristics of the subjects |
|-------------------------------------------------------------|
| Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
| Age (yrs) | 38.7 ± 10.5 | 43.1 ± 8.9 | 41.8 ± 9.5 |
| Height (cm) | 161.6 ± 3.2 | 158.8 ± 4.2 | 159.6 ± 4.4 |
| Weight (kg) | 66.7 ± 5.3 | 68.1 ± 8.2 | 67.8 ± 7.4 |
| BMI (kg/m²) | 25.5 ± 10.3 | 27.1 ± 3.0 | 26.7 ± 2.8 |
| Body fat (%) | 35.1 ± 4.4 | 37.4 ± 4.2 | 36.0 ± 4.3 |
| Waist circumferences (cm) | 84.8 ± 7.8 | 86.4 ± 6.5 | 85.4 ± 7.3 |
| Hip circumferences (cm) | 98.8 ± 5.0 | 102.1 ± 3.8 | 100.1 ± 4.9 |
| WHR** | 0.90 ± 0.06 | 0.92 ± 0.04 | 0.90 ± 0.05 |

1) Controls: obese female without dyslipidemia; 2) Obese with dyslipidemia: Subjects who met the criteria of BMI ≥ 23, total cholesterol ≥ 200 mg/dL, LDL cholesterol ≥ 130 mg/dL, and TG ≥ 110 mg/dL. 3) Mean ± SD; 4) WHR (Waist-Hip ratio) calculated by dividing WC/HC; 5) Significant by t-test.

| Table 2. Blood lipid profiles of the subjects |
|---------------------------------------------|
| Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
| Total cholesterol (mg/dL) | 172.6 ± 13.3 | 216.5 ± 22.6 | 190.3 ± 27.7 |
| Triglyceride (mg/dL) | 82.2 ± 58.7 | 120.5 ± 32.5 | 99.6 ± 56.8 |
| LDL-cholesterol (mg/dL) | 94.7 ± 12.1 | 138.8 ± 28.5 | 112.1 ± 26.5 |
| HDL-cholesterol (mg/dL) | 59.7 ± 11.3 | 55.4 ± 9.2 | 581 ± 10.3 |
| Total cholesterol / HDL | 2.67 ± 0.62 | 4.04 ± 0.91 | 3.54 ± 0.93 |
| LDL / HDL | 1.65 ± 0.45 | 2.61 ± 0.75 | 2.03 ± 0.74 |

1,2,3) see the table 1. 4) P<0.05, *** P<0.001 by t-test, 5) not significant by t-test.
Blood biochemical analysis of the subjects
Table 3 describes the results of the blood biochemical analysis in subjects. The concentrations of plasma hemoglobin, albumin, and creatine between two groups were similar. Blood SGOT and SGPT level were higher in obese with dyslipidemia than in the control group, but no statistical significance was shown. Blood alkaline phosphatase (ALP) level was statistically different between the two groups; 63.8 ± 13.5 U/mL in obese with dyslipidemia and 51.9 ± 15.6 U/mL in the control group. The concentrations of plasma hemoglobin, albumin, and creatine between two groups were similar. Blood SGOT and SGPT were higher in obese with dyslipidemia than in the control group, but no statistical significance was shown.

Table 3. Blood biochemical analysis of the subjects

|                        | Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
|------------------------|-------------------|----------------------------------|----------------|
| Hemoglobin (g/dL)      | 13.3 ± 1.2        | 13.9 ± 0.7                      | 13.3 ± 0.9     |
| Albumin (mg/dL)        | 4.58 ± 0.13       | 4.47 ± 0.17                     | 4.53 ± 0.14     |
| Creatine (mg/dL)       | 0.83 ± 0.14       | 0.82 ± 0.11                     | 0.82 ± 0.16     |
| BUN (mg/dL)4)          | 11.7 ± 3.8        | 13.4 ± 2.89                     | 12.4 ± 2.55     |
| SGOT (Units/L)5)       | 19.8 ± 5.8        | 21.1 ± 4.5                      | 20.4 ± 5.2      |
| SGPT (Units/L)6)       | 15.4 ± 7.3        | 17.5 ± 7.9                      | 17.0 ± 7.7      |
| ALP (U/mL)7)           | 519.1 ± 15.6      | 638.8 ± 13.5                    | 604. ± 14.6     |
| Glucose (mg/dL)        | 87.2 ± 15.2       | 93.3 ± 10.9                     | 91.8 ± 13.1     |
| r-GTP (Units/L)8)      | 19.7 ± 10.7       | 27.4 ± 18.9                     | 25.1 ± 16.8     |

5) SGOT: serum glutamic oxalate transaminase.
6) SGPT: serum glutamic pyruvate transaminase.
7) ALP: alkaline phosphatase.
8) r-GTP: r-glutammyl transpeptidase.

Comparing the dietary consumptions between two groups, obese with dyslipidemia group consumed higher level of mean percentage comparisons to the KDRI in all nutrients surveyed, but the differences were not statistically significant. The obese with dyslipidemia seemed to have higher mean percentage comparisons to the KDRI of energy and nutrient intakes in all nutrients, but the differences were not statistically significant. Among the antioxidant enzymes, the concentrations of GSH-Px and catalase were significantly

Table 4. Percentage comparisons to the KDRI of energy and nutrient intakes in subjects

|                        | Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
|------------------------|-------------------|----------------------------------|----------------|
| Calorie4)              | 88.2 ± 17.4       | 91.8 ± 22.4                      | 88.9 ± 20.5    |
| Protein                | 134.4 ± 43.6      | 153.8 ± 59.9                     | 141.0 ± 51.6   |
| Cholesterol            | 96.7 ± 35.7       | 110.6 ± 32.6                     | 102.4 ± 34.0   |
| Dietary fiber          | 83.9 ± 36.7       | 84.7 ± 44.8                      | 84.0 ± 40.8    |
| Vitamin A              | 111.5 ± 72.5      | 139.7 ± 61.4                     | 121.1 ± 66.5   |
| Vitamin E              | 143.3 ± 55.3      | 152.1 ± 48.4                     | 146.2 ± 61.2   |
| Vitamin C              | 74.0 ± 46.0       | 80.1 ± 48.7                      | 76.9 ± 34.6    |
| Vitamin B1             | 99.7 ± 31.0       | 107.5 ± 45.9                     | 105.4 ± 38.9   |
| Vitamin B2             | 94.3 ± 45.7       | 99.6 ± 42.8                      | 96.9 ± 43.9    |
| Niacin                 | 101.4 ± 39.4      | 108.8 ± 40.9                     | 105.0 ± 39.8   |
| Vitamin B6             | 94.4 ± 33.7       | 107.8 ± 37.2                     | 100.0 ± 35.6   |
| Folate                 | 119.8 ± 56.9      | 136.8 ± 48.6                     | 128.1 ± 53.1   |
| Calcium                | 70.3 ± 28.9       | 84.8 ± 36.4                      | 77.4 ± 33.3    |
| Phosphorus             | 143.2 ± 40.4      | 155.9 ± 59.9                     | 149.0 ± 50.7   |
| Sodium                 | 243.3 ± 83.5      | 278.7 ± 102.6                    | 260.6 ± 93.9   |
| Potassium              | 626.5 ± 32.1      | 75.1 ± 21.9                      | 67.6 ± 29.4    |
| Iron                   | 96.8 ± 36.5       | 105.9 ± 38.8                     | 101.2 ± 37.3   |
| Zinc                   | 109.4 ± 31.0      | 122.3 ± 41.8                     | 115.7 ± 36.8   |

Table 5. Plasma concentrations of lipid peroxidation, total antioxidant capacity, and antioxidant enzymes of the subjects

|                        | Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
|------------------------|-------------------|----------------------------------|----------------|
| Lipid peroxidation (nmol/mL) | 1.09 ± 0.97 | 1.31 ± 0.84                      | 1.25 ± 0.87    |
| Total antioxidant capacity (nmol Trolox eqv./L) | 1.70 ± 0.52 | 1.57 ± 0.61                      | 1.61 ± 0.58    |
| GSH-Px (U/mL)4) | 54.18 ± 16.61 | 42.65 ± 14.60                    | 50.63 ± 16.72   |
| SOD (U/mL)5) | 15.11 ± 5.53 | 13.87 ± 4.84                      | 14.78 ± 5.32    |
| Catalase (U/mL)6) | 3.97 ± 1.65 | 2.73 ± 1.59                      | 3.58 ± 1.71    |

4) EER (Estimated energy requirement) for energy, AI (Adequate intake) for dietary fiber, sodium, potassium, vitamin E, RNI (Recommended nutrient intake) for other nutrients.
5) NS not significant by t-test.
6) * P < 0.05 by t-test.

Blood lipid peroxidation and antioxidative enzyme activities of the subjects
The oxidant and antioxidant status of subjects is shown at Table 5. Plasma thiobarbituric acid reactive substances (TBARS) concentration, as a marker of lipid peroxidation, was determined. A slightly higher concentration of TBARS, without statistical significance, was found in obese with dyslipidemia than in the control group. The plasma total antioxidant capacity (TAC) was lower in obese group with dyslipidemia, but the group difference was not statistically significant. Among the antioxidant enzymes, the concentrations of GSH-Px and catalase were significantly

Table 6. Plasma antioxidant-vitamin concentrations of the subjects

|                        | Controls (N = 23) | Obese with dyslipidemia (N = 19) | Total (N = 42) |
|------------------------|-------------------|----------------------------------|----------------|
| α-tocopherol (mg/dL)   | 0.40 ± 0.11       | 0.39 ± 0.08                      | 0.40 ± 0.11    |
| α-tocopherol /cholesterol (mg/dL) | 0.23 ± 0.43 | 0.18 ± 0.07                      | 0.21 ± 0.06    |
| Retinol (ug/dL)4)      | 35.3 ± 7.8        | 29.1 ± 7.85                      | 32.0 ± 7.76    |
| Retinol/cholesterol (mg/dL) | 0.021 ± 0.04 | 0.014 ± 0.04                     | 0.014 ± 0.04   |
| β-carotene (mg/dL)8)   | 28.4 ± 6.53       | 27.4 ± 3.01                      | 28.1 ± 5.47    |

4) EER (Estimated energy requirement) for energy, AI (Adequate intake) for dietary fiber, sodium, potassium, vitamin E, RNI (Recommended nutrient intake) for other nutrients.
8) * P < 0.05 by t-test.
lower in obese group with dyslipidemia than in the control group; The GSH-Px activity (U/mL) was 54.18 ± 16.61 for obese group with dyslipidemia and 42.65 ± 14.60 for the control group ($P < 0.05$). The catalase activity (U/mL) was 2.73 ± 1.59 for obese group with dyslipidemia and 3.97 ± 1.65 for the control group ($P < 0.05$). There was no significant differences of the SOD activity between the two groups.

**Blood antioxidative vitamins concentration of the subjects**

The concentrations of antioxidative vitamins in subjects are present in Table 6. The obese with dyslipidemia had lower levels of plasma α-tocopherol and retinol than the control group, but this was not statistically significant. However, when those values were adjusted with plasma total cholesterol, adjusted α-tocopherol level was significantly lower in obese with dyslipidemia than in the control group ($P < 0.05$). Adjusted retinol level of obese with dyslipidemia was also significantly lower than that of the control group ($P < 0.05$). No significant differences of plasma concentrations of β-carotene, lycopene, and lutein between two groups were found.

**Blood Adiponectin and leptin concentration of the subjects**

The plasma concentrations of adiponectin and leptin are described in Fig. 1 and Fig. 2 respectively. The plasma concentration of leptin was significantly higher in obese with dyslipidemia (15,406 ± 3,513 pg/mL) than in the control group (12,943 ± 1810 pg/mL) ($P < 0.05$). The levels of plasma adiponectin in obese with dyslipidemia (5,560.5 ± 741.3 ng/mL) was lower than that in the control group (6,256.2 ± 979.9 ng/mL), but the difference was not statistically significant.

**DISCUSSION**

Excessive weight can result in many serious health problems. Lipid abnormalities have been reported in obese adults and even in obese children and adolescents [9-11]. However, not all obese people have blood lipid abnormalities. It is believed that adipocyte dysfunction occurs as a result of excess fat accumulation in the body, which cause abnormal secretion of adipokines, herby contributing to the pathogenesis of obesity related metabolic abnormalities or diseases. Thus, we tried to compare the plasma adipokines and antioxidative systems expressed by adipokines between obese with dyslipidemia and obese without dyslipidemia.

Study subjects were characterized as the females whose BMI is 23 or greater. In Korea, overweight is defined as the BMI value between 23 and 24.9 and obese as the value of 25 or greater [24]. WHO Expert Consultation suggested lower BMIs cut-off point at 23 for overweight in Asian population, in comparison to western BMI cut-off points for overweight (BMI ≥ 23 kg/m²) [25]. A study reported that this lowered BMI as a cut-off point for overweight in Asian population was suitable because this BMI value is significantly associated with risks of chronic diseases [26].

The measurements of LDL-C/HDL-C ratio and TC/HDL-C ratio are often used as markers of estimate CHD risk, especially ischemic heart disease (IHD) [32]. In this study, obese females with dyslipidemia showed significantly higher values of TC/HDL-C ratio (4.04 ± 0.91) than the control group (2.67 ± 0.62), which suggests that obese females with dyslipidemia have high risk of CHD risk. LDL/HDL ratio, as another index for CHD risk was also significantly higher in obese with dyslipidemia than in the control group, but ratio in both group were within the
normal range. It has been suggested that atherogenic metabolic disturbances may not always be adequately reflected by the variation in the LDL-C/HDL-C ratio because VLDL contains more cholesterol and the relative cholesterol content of VLDL increased across TG quintiles [28,29]. Instead, TC/HDL-C ratio has been reported as a better indicator of the presence of atherogenic dyslipidemia [28].

Blood level of alkaline phosphatase (ALP) was significantly higher in obese with dyslipidemia than in the control group. ALP is a hydrolase enzyme responsible for removing phosphate groups and it is mainly derived from the liver, bones, intestines, kidneys, and leukocytes [30]. Several studies have suggested that high serum ALP levels increased vascular calcification and thus further increased risk of cardiovascular disease (CVD) [30,31]. The association between ALP and CVD may be linked with inflammation mechanism, due to the incapability of dephosphorylating potentially deleterious molecules [31]. Thus an increased ALP level in obesity with dyslipidemia may cause an increase in oxidative stress, and further inflammation, and so careful monitoring of ALP in obese population is maybe needed.

Regarding dietary recall data, all obese females in this study had high consumption of sodium but low consumption of potassium, compared to the mean percentage to the KDRIs of those nutrients. Overconsumption of sodium intake is more strongly associated with metabolic syndromes, especially hypertension, in obese people than normal weight people [32]. The consumption of potassium in the diet has been found to reduce the harmful effects of dietary salt in humans, lowering blood pressure and improving hypertension control [33,34]. Thus careful monitoring of sodium and potassium intake is especially necessary for obese people to reduce the health risk.

Free radicals are type of oxygen-related molecules with high levels of oxidizing power, damaging body tissues. Adipose tissue possesses relatively high levels of antioxidant defensive enzymes for managing high ROS production [7]. However, if the amount of oxygen-free radicals created in adipose tissue surpasses the amount of antioxidant capacities, oxidative stress increases. In this study, the antioxidant enzymes activities, such as GSH-Px and catalase were significantly less in the obese with dyslipidemia group. Studies have reported low levels of antioxidant enzymes in obese individuals [35-37]. Thus this result indicates that a decrease in antioxidant enzymes may lead to enhanced oxidative stress in the adipose tissue of obese subjects.

The blood retinol and tocopherol in obese with dyslipidemia, after adjusted with total blood cholesterol, were significantly lower than those in the control group. Mehmetoglu et al. [38] reported that only after vitamin A level adjusted with cholesterol level, blood retinol concentration in obese group was significantly lower than the healthy weight group. Vitamin A is especially emerging as a factor of interest in relation to cardiovascular disease [39,40]. A low plasma retinol was associated with about a three-time increase in the risk of cardiovascular-related diseases [40]. The supplementation with vitamin A in obesity has been found to be beneficial to a number of inflammatory conditions [41,42].

In contrast, leptin in this study was significantly higher in obese with dyslipidemia than in the control group. Researchers have found that leptin not only affects appetite, but also produces reactive oxygen species that induces functional damage in endothelial cells [43,44]. Animal studies suggested that increased leptin level in obese rat, through induction of iNOS and NADPH oxidase, caused the peroxynitrite-mediated oxidative stress [45]. Our study results of decreased antioxidants and the increased leptin support our hypothesis that obesity with dyslipidemia will cause lower antioxidant protection and increased oxidative stress than obesity without dyslipidemia.

This study showed no significant differences for age, BMI, and body fat (%) between two groups (Table 1), but significantly abnormal blood lipids profiles in obese with dyslipidemia group compared to the control group. In addition, there were no significant differences in dietary intakes between two groups, and thus the results antioxidants-study seem unlikely to be dietary effect. The results of this study are may possibly dependent on the status of dyslipidemia, not obesity degree. Our study is limited by the small size of the study population, and thus more studies with large sample size are needed to clear our findings. In addition, although it is enhanced by oxidant and several antioxidants measured, another limitation of this study is not having measured various markers of lipid peroxidation or inflammation. The present study however, provides some evidence suggesting that dyslipidemia in obesity are related with abnormal secretions of adipokines and depletion of antioxidative system, the two factors which are associated with increased CHD risk.

In conclusion, obese female with dyslipidemia in this study showed lower antioxidant capacities, such as depleted levels of GSH-Px and catalase, retinol, and tocopherol, and a higher concentration of blood leptin, than obese female who have normal lipid profiles. This imbalance between pro-inflammatory adipocytokines and depleted antioxidant status are related with higher CHD risk in obese females with dyslipidemia. Thus to prevent such risks, it is most important to maintain a proper weight through a balanced diet, especially proper sodium and potassium intakes. In addition, proper intakes of antioxidant nutrients will be helpful in maintaining health in obese population with dyslipidemia.

REFERENCES

1. Ministry of Health and Welfare, Korea Centers for Disease Control and Prevention. Korea Health Statistics 2009: Korea National Health and Nutrition Examination Survey(KNHANES IV-3). Cheongwon: Korea Centers for Disease Control and Prevent; 2010.
2. Calori G, Lattuada G, Piemonti L, Garancini MP, Ragogna F, Villa M, Mannino S, Ciosignani P, Bosi E, Luzi L, Ruotolo G, Perseghin G. Prevalence, metabolic features, and prognosis of metabolically healthy obese Italian individuals: the Cremona Study. Diabetes Care 2011;34:210-5.
3. Song Y, Manson JE, Meigs JB, Ridker PM, Buring JE, Liu S. Comparison of usefulness of body mass index versus metabolic risk factors in predicting 10-year risk of cardiovascular events in women. Ann J Cardiol 2007;100:1654-8.
4. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 2012;97:2482-8.
5. Perségol L, Vergès B, Gambert P, Duvillard L. Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation. J Lipid Res 2007;48:1396-401.

6. Lima SC, Arrais RF, Almeida MG, Souza ZM, Pedrosa LF. Plasma lipid profile and lipid peroxidation in overweight or obese children and adolescents. J Pediatr (Rio) 2004;80:23-8.

7. Yang RL, Shi YH, Hao G, Li W, Le GW. Increasing oxidative stress with progressive hyperlipidemia in human: relation between malondialdehyde and atherogenic index. J Clin Biochem Nutr 2008;43:154-8.

8. Bolkent S, Yanardag R, Bolkent S, Döger MM. Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats. Biol Trace Elem Res 2004;101:219-29.

9. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56.

10. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature 1996;380:677.

11. Arita Y, Kihara S, Ouchi N, Takahashi K, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguechi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.

12. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell 2001;104:531-43.

13. Savini I, Catani MV, Evangelista D, Gasperi V, Avigliano L. Obesity-related oxidative stress: strategies finalized to improve redox state. Int J Mol Sci 2013;14:4979-53.

14. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007;39:44-84.

15. McGee DL, Diverse Populations C. Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies. Ann Epidemiol 2005;15:87-97.

16. Fridewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972;18:499-502.

17. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.

18. Rice-Evans CA. Measurement of total antioxidant activity as a marker of antioxidant status in vivo: procedures and limitations. Free Radic Res 2000;33 Suppl1:559-66.

19. Aebi H. Catalase in vitro. Methods Enzymol 1984;105:121-6.

20. Fridovich I. Superoxide radical: an endogenous toxicant. Annu Rev Pharmacol Toxicol 1983;23:229-57.

21. Filella J, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.

22. Catignani GL, Bieri JG. Simultaneous determination of retinol and alpha-tocopherol in serum or plasma by liquid chromatography. Clin Chem 1983;29:708-12.

23. Craft NE, Brown ED, Smith JC Jr. Effects of storage and handling conditions on concentrations of individual carotenoids, retinol, and tocopherol in plasma. Clin Chem 1988;34:44-8.

24. Goh VH, Tain CF, Tong TY, Mok HP, Wong MT. Are BMI and other anthropometric measures appropriate as indices for obesity? A study in an Asian population. J Lipid Res 2004;45:1892-8.

25. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.

26. Iwao N, Iwao S, Muller DC, Koda M, Ando F, Shimokata H, Kobayashi F, Andres R. Differences in the relationship between lipid CHD risk factors and body composition in Caucasians and Japanese. Int J Obes (Lond) 2005;29:228-35.

27. Shin HH. Korean guidelines of hyperlipidemia treatment for prevention of atherosclerosis. J Korean Soc Lipidol Atheroscler 2002;12:226-8.

28. Lemieux I, Lamarche B, Couillard C, Pacson A, Cantin B, Bergeron J, Dagenais GR, Després JP. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study. Arch Intern Med 2001;161:2685-92.

29. Leroux G, Lemieux I, Lamarche B, Cantin B, Dagenais GR, Lupien PJ, Després JP. Influence of triglyceride concentration on the relationship between lipoprotein cholesterol and apolipoprotein B and A-I levels. Metabolism 2000;49:53-61.

30. Pike AF, Kramer Nl, Blaauwboer BJ, Seinen W, Brands R. A novel hypothesis for an alkaline phosphatase ‘rescue’ mechanism in the hepatic acute phase immune response. Biochim Biophys Acta 2013;1832:2044-56.

31. Ryu WS, Lee SH, Kim CK, Kim BJ, Yoon BW. Increased serum alkaline phosphatase as a predictor of long-term mortality after stroke. Neurology 2010;75:1995-2002.

32. Cook NR, Obarzanek E, Cutler JA, Buring JE, Rexrode KM, Kuminyika SK, Appel LJ, Whelton PK; Trials of Hypertension Prevention Collaborative Research Group. Joint effects of sodium and potassium intake on subsequent cardiovascular disease: the Trials of Hypertension Prevention follow-up study. Arch Intern Med 2009;169:32-40.

33. Kido M, Ando K, Onozato ML, Tojo A, Yoshikawa M, Ogita T, Fujita T. Protective effect of dietary potassium against vascular injury in salt-sensitive hypertension. Hypertension 2008;51:225-31.

34. Matsui H, Shimosawa T, Uetake Y, Wang H, Ogura S, Kaneko T, Liu J, Ando K, Fujita T. Protective effect of potassium against the hypertensive cardiac dysfunction: association with reactive oxygen species reduction. Hypertension 2006;48:225-31.

35. Okuno Y, Matsuda M, Kobayashi H, Morita K, Suzuki E, Fukuhara A, Komuro R, Shimabukuro M, Shimomura I. Adipose expression of catalase is regulated via a novel remote PPARgamma-responsive region. Biochem Biophys Res Commun 2008;366:698-704.

36. Sharma R, Sharma A. Effect of obesity on antioxidant enzymes and type 2 diabetes. Indian J Clin Biochem 2007;22 Suppl:259-65.

37. Waggiallah I, Alzohairy M. The effect of oxidative stress on human red cells glutathione peroxidase, glutathione reductase level, and prevalence of anemia among diabetics. N Am J Med Sci 2011;3:344-7.

38. Mehmetoglu I, Yerlikaya FH, Kurtan S. Correlation between vitamin A, E, coenzyme Q(10) and degree of insulin resistance in obese and non-obese subjects. J Clin Biochem Nutr 2011;49:159-63.

39. Gey KF, Ducimetière P, Evans A, Amouyel P, Arveiler D, Ferrière J, Luc G, Koo F, Bingham A, Yarnell J, Cambien F. Low plasma retinol predicts coronary events in healthy middle-aged men: the PRIME Study. Atherosclerosis 2010;208:270-4.

40. Brazionis L, Walker KZ, Itsiopoulos C, O'Dea K. Plasma retinol: a novel marker for cardiovascular disease mortality in Australian adults. Nutr Metab Cardiovasc Dis 2012;22:914-20.

41. Reifen R. Vitamin A as an anti-inflammatory agent. Proc Nutr Soc
42. Gushchina LV, Yasmeen R, Ziouzenkova O. Moderate vitamin A supplementation in obese mice regulates tissue factor and cytokine production in a sex-specific manner. Arch Biochem Biophys 2013;539:239-47.

43. Bouloumie A, Marumo T, Lafontan M, Busse R. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13:1231-8.

44. Das S, Kumar A, Seth RK, Tokar EJ, Kadiiska MB, Waalkes MP, Mason RP, Chatterjee S. Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity. Toxicol Appl Pharmacol 2013;269:297-306.

45. Chatterjee S, Ganini D, Tokar EJ, Kumar A, Das S, Corbett J, Kadiiska MB, Waalkes MP, Diehl AM, Mason RP. Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis. J Hepatol 2013;58:778-84.